Open AccessP105 (0032) A PHASE II STUDY OF PEMBROLIZUMAB (PEM) FOLLOWED BY AVD FOR FRONTLINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA (CHL): INTERIM RESULTS
Publication year - 2018
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000547951.52640.26
Subject(s) - interim , pembrolizumab , lymphoma , medicine , political science , cancer , law , immunotherapy